SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001527599-17-000018
Filing Date
2017-08-04
Accepted
2017-08-03 17:33:06
Documents
55
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 MIRNA THERAPEUTICS 10-Q mirn_063017x10qdocument.htm 10-Q 829163
2 EXHIBIT 31.1 CEO CERTIFICATION mirn_06302017x10qex311.htm EX-31.1 13558
3 EXHIBIT 31.2 CFO CERTIFICATION mirn_063017x10qex312.htm EX-31.2 13589
4 EXHIBIT 32.1 CERTIFICATION mirn_06302017x10qex321.htm EX-32.1 8787
  Complete submission text file 0001527599-17-000018.txt   3951935

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mirn-20170630.xml EX-101.INS 777882
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mirn-20170630.xsd EX-101.SCH 31642
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mirn-20170630_cal.xml EX-101.CAL 44098
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mirn-20170630_def.xml EX-101.DEF 138280
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mirn-20170630_lab.xml EX-101.LAB 407878
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mirn-20170630_pre.xml EX-101.PRE 227431
Mailing Address 2150 WOODWARD ST., SUITE 100 AUSTIN TX 78744
Business Address 3711 SOUTH MOPAC EXPRESSWAY, STE 100 AUSTIN TX 78746 512-901-0900
Mirna Therapeutics, Inc. (Filer) CIK: 0001527599 (see all company filings)

IRS No.: 261824804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37566 | Film No.: 171006217
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences